Details
Stereochemistry | ACHIRAL |
Molecular Formula | Cr |
Molecular Weight | 51.9961 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cr]
InChI
InChIKey=VYZAMTAEIAYCRO-UHFFFAOYSA-N
InChI=1S/Cr
Molecular Formula | Cr |
Molecular Weight | 51.9961 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Nearly 60 years ago, chromium, as the trivalent ion, was proposed to be an essential element, but the results of new studies indicate that chromium currently can only be considered pharmacologically active and not an essential element. Chromium is a mineral that humans need in very small quantities. Good sources include broccoli, liver, and brewers' yeast. Taking chromium by mouth is effective for preventing chromium deficiency. It is also taken by mouth for depression, Turner's syndrome, polycystic ovary syndrome (PCOS), lowering "bad" cholesterol, raising "good" cholesterol in people taking heart medications called beta blockers, obesity, metabolic syndrome, heart attack, schizophrenia, bipolar disorder, binge eating disorder, and a disease called reactive hypoglycemia. Chromium has been marketed as an agent to reduce body mass and develop muscle; however, such marketing claims are no longer allowed in the United States because they are not supported by experiments. Trivalent chromium has also been proposed as a therapeutic agent to increase insulin sensitivity and affect lipid metabolism. Although effective in certain rodent models, beneficial effects in humans have not been unequivocally established.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
In vivo nephrotoxicity induced in mice by chromium(VI). Involvement of glutathione and chromium(V). | 1991 Oct |
|
Effect of chromium on the insulin resistance in patients with type II diabetes mellitus. | 2005 |
|
The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats. | 2006 |
|
Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. | 2006 Aug |
|
Cytogenetic effects of a mixture of selected metals following subchronic exposure through drinking water in male rats. | 2006 Dec |
|
Lactoferrin and bone; structure-activity relationships. | 2006 Jun |
|
Effect of chromium on vertebrae, femur and calvaria of adult male rats. | 2006 Jun |
|
Conjugated linoleic acid and chromium lower body weight and visceral fat mass in high-fat-diet-fed mice. | 2006 May |
|
Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium. | 2006 Nov 27 |
|
High-dose chromium(III) supplementation has no effects on body mass and composition while altering plasma hormone and triglycerides concentrations. | 2006 Oct |
|
Chromium and vanadate combination increases insulin-induced glucose uptake by 3T3-L1 adipocytes. | 2006 Sep 1 |
|
Reproductive toxicity of chromium in adult bonnet monkeys (Macaca radiata Geoffrey). Reversible oxidative stress in the semen. | 2006 Sep 15 |
|
Multivariate analysis of the selected metals in the hair of cerebral palsy patients versus controls. | 2006 Summer |
|
Effect of dietary chromium on resistance artery function and nitric oxide signaling in the sucrose-fed spontaneously hypertensive rat. | 2007 |
|
Arsenite and cadmium, but not chromium, induce NAD(P)H:quinone oxidoreductase 1 through transcriptional mechanisms, in spite of post-transcriptional modifications. | 2008 Aug |
|
Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells. | 2008 Feb 1 |
|
Cholesterol efflux and the effect of combined treatment with niacin and chromium on aorta of hyperlipidemic rat. | 2008 Jan |
|
Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. | 2008 Jan |
|
Blood pressure lowering effects of niacin-bound chromium(III) (NBC) in sucrose-fed rats: renin-angiotensin system. | 2008 Jul |
|
Chromium (VI) induces insulin resistance in 3T3-L1 adipocytes through elevated reactive oxygen species generation. | 2008 Jun |
|
Deposition of nickel, chromium, and cobalt on the skin in some occupations - assessment by acid wipe sampling. | 2008 Jun |
|
Gene expression profiles in rainbow trout, Onchorynchus mykiss, exposed to a simple chemical mixture. | 2008 Mar |
|
Chromium (D-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. | 2008 Oct |
|
Chromium-mediated apoptosis: involvement of DNA-dependent protein kinase (DNA-PK) and differential induction of p53 target genes. | 2008 Sep 1 |
|
The effects of feeding with different levels of zinc and chromium on plasma thiobarbituric acid reactive substances and antioxidant enzymes in rats. | 2009 |
|
Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HlJ diabetic mice. | 2009 Apr |
|
Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells. | 2009 Apr |
|
Trivalent chromium activates Rac-1 and Src and induces switch in the cell death mode in human dermal fibroblasts. | 2009 Aug 10 |
|
Effect of chromium supplementation on the diabetes induced-oxidative stress in liver and brain of adult rats. | 2009 Dec |
|
Chromium supplement inhibits skeletal muscle atrophy in hindlimb-suspended mice. | 2009 Dec |
|
Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. | 2009 Jan |
|
Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats. | 2009 Jul |
|
Response to chronic exposure to hexavalent chromium in human monocytes. | 2009 Jun |
|
Chromium(III) induces oxidative stress in goldfish liver and kidney. | 2009 Jun 4 |
|
Protective effects of combined micronutrients on islet beta-cells of streptozotocin-induced diabetic mice. | 2009 Mar |
|
Multiple metals predict prolactin and thyrotropin (TSH) levels in men. | 2009 Oct |
|
Chronic maternal dietary chromium restriction modulates visceral adiposity: probable underlying mechanisms. | 2010 Jan |
|
Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HlJ mice. | 2010 Jul 2 |
|
Maternal dietary chromium restriction programs muscle development and function in the rat offspring. | 2010 Mar |
|
Evaluation of insulin binding and signaling activity of newly synthesized chromium(III) complexes in vitro. | 2010 Mar-Apr |
|
Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass. | 2010 May |
|
Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. | 2010 May |
|
Chromium improves protein deposition through regulating the mRNA levels of IGF-1, IGF-1R, and Ub in rat skeletal muscle cells. | 2010 Nov |
|
Simultaneous analysis of the local and systemic immune responses in mice to study the occupational asthma mechanisms induced by chromium and platinum. | 2010 Nov 9 |
|
Chromium (VI) inhibits mouse metallothionein-I gene transcription by modifying the transcription potential of the co-activator p300. | 2011 Apr |
|
Chromium improves production and alters metabolism of early lactation cows in summer. | 2011 Feb |
|
Chromium (D-phenylalanine)3 alleviates high fat-induced insulin resistance and lipid abnormalities. | 2011 Jan |
|
Cardioprotective effects of selenium on chromium (VI)-induced toxicity in female rats. | 2011 Mar |
|
Comparison of gene expression profiles in chromate transformed BEAS-2B cells. | 2011 Mar 18 |
|
The effects of chromium complex and level on glucose metabolism and memory acquisition in rats fed high-fat diet. | 2011 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/chromium.html
Curator's Comment: Chromium is also used intravenously (by IV) as a supplement in nutritional IV drips. https://www.webmd.com/vitamins/ai/ingredientmono-932/chromium
The currently accepted value for chromium dietary intake is 25 mcg/day for women and 35 mcg/day for men. Daily dosages used in clinical trials for periods of up to 9 months range as follows: brewer's yeast up to 400 mcg/day; chromium chloride 50 to 600 mcg/day; chromium nicotinate 200 to 800 mcg/day; chromium picolinate 60 to 1,000 mcg/day. The potential for genotoxic effects exists at higher dosages.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:23:21 GMT 2025
by
admin
on
Mon Mar 31 18:23:21 GMT 2025
|
Record UNII |
0R0008Q3JB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 581
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 586
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 583
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 578
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NCI_THESAURUS |
C637
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 590
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 588
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 579
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 584
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 580
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NCI_THESAURUS |
C896
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 582
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 589
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 585
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 591
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 587
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID3031022
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
2496
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
N0000171131
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
C370
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
0R0008Q3JB
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
m3505
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
910
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
100000090349
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
28073
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
N0000184306
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
DB11136
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
SUB13362MIG
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
D002857
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
0R0008Q3JB
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
231-157-5
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
23976
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
N0000175629
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
7440-47-3
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
CHROMIUM (ng/cigarette)
Canadian = 353.3 SD(115.3)
Imported = 581.4 SD(103.0)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |